AGM Statement

Alliance Pharma PLC
12 May 2006


For immediate release                                                12 May 2006



                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                                 AGM Statement


Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
held its Annual General Meeting earlier today at which all resolutions were duly
passed.


Michael Gatenby, the Company's Chairman, made the following comments: 'I am
pleased to report that trading for the year to date is in line with management
expectations. We are benefiting from the recent acquisition of the Hydromol
range of dermatology products and we continue to look for further appropriate
opportunities to bring additional products into our portfolio.


'Our pipeline products are moving closer to regulatory submission. Phase III
clinical trials are on-going and, as part of our pre-marketing activities, we
continue to work closely with leading clinicians and recently held a successful
symposium on the use of melatonin for sleep disorders held last month at the
Royal Society of Medicine in London.'



For further information:

Alliance Pharma plc                                         + 44 (0)1249 466 966
                                                                          
John Dawson, Chief Executive

Maddy Scott, Finance Director

www.alliancepharma.co.uk

Buchanan Communications                                     + 44 (0)20 7466 5000
                                                                       
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich



Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.


Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.


Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for
the induction of labour.


Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.


                      This information is provided by RNS
            The company news service from the London Stock Exchange